Analysts at Raymond James Financial began coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) in a research report issued on Thursday, Marketbeat reports. The brokerage set a "moderate buy" rating on the stock.
ODTX has been the subject of a number of other research reports. Weiss Ratings initiated coverage on shares of Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a "sell (d+)" rating for the company. JPMorgan Chase & Co. boosted their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. HC Wainwright began coverage on Odyssey Therapeutics in a research note on Thursday, August 27th. They issued a "buy" rating and a $44.00 price objective on the stock. Oppenheimer reiterated an "outperform" rating and issued a $40.00 target price on shares of Odyssey Therapeutics in a report on Thursday, June 18th. Finally, Wall Street Zen downgraded Odyssey Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 20th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.00.
Get Our Latest Report on Odyssey Therapeutics
Odyssey Therapeutics Stock Up 4.9%
Shares of Odyssey Therapeutics stock opened at $19.00 on Thursday. The firm's 50-day moving average price is $22.76. Odyssey Therapeutics has a 12 month low of $15.10 and a 12 month high of $29.05. The stock has a market cap of $913.14 million and a PE ratio of -2.81.
Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. Equities research analysts anticipate that Odyssey Therapeutics will post -6.20 EPS for the current year.
Hedge Funds Weigh In On Odyssey Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp acquired a new stake in Odyssey Therapeutics in the second quarter valued at $1,477,000. Citadel Advisors LLC acquired a new position in shares of Odyssey Therapeutics during the 2nd quarter worth about $4,162,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Odyssey Therapeutics in the 2nd quarter valued at about $601,000.
Odyssey Therapeutics Company Profile
(
Get Free Report)
Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.
Odyssey's research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.
Further Reading
Before you consider Odyssey Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Odyssey Therapeutics wasn't on the list.
While Odyssey Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
